Skip to Content
  • Drug Prices

    More on Drug Prices

    I can strongly recommend this piece from Robert Bartley in the Wall Street Journal today. It’s a clear-eyed look at the issues involved. There are a couple of misconceptions in it, though. He mentions an “acquisition” of Imclone by Bristol-Meyers Squibb, but their deal was always about clinical candidates, not acquisition. BMS did… Read More
  • Animal Testing

    You’ll Only Get Answers

    I mentioned the other day that I’ve usually had a good response when I tell people about what I do for a living. There are exceptions, though. A few years ago, my wife and I were walking through a shopping mall, when we were stopped by two scruffy teenage survey takers. “Would you like to… Read More
  • Drug Prices

    The Dismal Science of Drug Prices

    I’m a little disconcerted by Instapundit’s endorsement today of the Wellstone drug reimportation bill. My position on this is closer to Andrew Sullivan’s (and the reader he quotes here.) That is to say, I believe prescription drugs aren’t correctly priced in Canada and overpriced here. They’re underpriced in Canada (an… Read More
  • Life in the Drug Labs

    Talk, Cheap and Otherwise

    Chad Orzel over at Uncertain Principles has a couple of long posts on giving public presentations as a scientist. My experiences parallel his: a 45-minute talk to your peers isn’t too hard to put together, while a 15-minute talk is. And a talk to a lay audience can be harder than either one! (I haven’t… Read More
  • Drug Development

    A Twisty Road

    The business news has been on top of the science news recently, that’s for sure. Maybe we can go a week or so without accounting issues, mergers, and whatnot. I wanted to call people’s attention to a good article in July 8 issue of The Scientist (free, but registration required.) It’s a history of a… Read More
  • Business and Markets

    Marketing Ueber Alles

    The Wall St. Journal’s “Heard on the Street” column today made the case that Pfizer’s expansion isn’t really about scientific research. It’s about marketing. They’ll have a monstrously huge sales force, a big advertising budget, and so on. The article makes many of the same points that I’ve been harpi… Read More
  • Business and Markets

    By Any Other Name

    Is it just me, or does it seem a little odd that there was no doubt about what the Pfizer-Pharmacia merged company would be called? Recall that Sandoz and Ciba-Geigy threw two well-established brand names out the window to become Novartis. And Aventis had no choice when it formed; it was such a mouthful that… Read More
  • Business and Markets

    The Apatosaurus. The Spruce Goose. The Pyramids

    The news this morning is full of the Pfizer/Pharmacia (aka Pharmacia-Upjohn) merger. Perhaps this will trigger the long-expected wave of further drug company consolidation (but, then again, the Pfizer/Warner-Lambert deal was supposed to do that, too.) I hope it doesn’t, but I have to admit that the industry is congealing, and has been for som… Read More
  • Business and Markets

  • Life in the Drug Labs

    More Pfizer Explosion Details

    A short, but detailed story about the Pfizer explosion is here, from C&E News. While I was out on vacation, more details came out. I’ve been meaning to correct my earlier reports that the blast started with lithium t-butoxide. It now appears that the cause was a drum of borane/THF, which makes even more sense. Read More